anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The prevalence of obesity in the Netherlands has been on the rise for decades and recent preventive efforts of government and other societal actors appear insufficient to reverse this trend. The development of food technologies neutralizing the impact of fat and sugar, and medicines that might help individuals losing weight could be seen as part of a solution. We argue however that these also reinforce three fundamental societal problems underlying the obesity crisis: a vicious market cycle, the framing of overweight as a problem of individuals, and an epistemological dilemma in science. Together these problems constitute a vicious circle that is especially harmful for socioeconomically disadvantaged groups. Many societal actors are involved in these problems and share moral responsibility for taking away the causes of injustice, including food industry, retailers, health care, and government. Effective prevention of obesity may require developing avenues to legally enforce these responsibilities.
This is a multicenter, prospective, single arm clinical study. The study will enroll 15 renal transplant recipients with positive DSA and CaAMR confirmed by biopsy after renal transplantation. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.
Participants in this arm will receive three weeks (30 session, twice-daily) of active Repetitive Transcranial Magnetic Stimulation. This arm will not involve random assignment.
Male and female volunteers received one dose of either DXM Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico). The drug was administered to 4 healthy subjects intranasally (treatment B). According to a randomization list generated prior to the start of the clinical phase.
Background: The ability to sit independently is fundamental for function but delayed in infants with cerebral palsy (CP). Studies of intervention directed specifically toward sitting in infants with CP have not been reported. Objective: Our purpose was to compare two interventions for improving sitting postural control in infants with CP. Design: For this randomized longitudinal study, infants under 2 years old and at risk for CP were recruited for intervention directed toward sitting independence. Setting: The intervention was conducted at home or at an outpatient facility. Patients: Fifteen typically developing infants (5 months old, SD .5 months at entry) were followed longitudinally as a comparison for postural variables. Thirty-five infants with delays in achieving sitting were recruited. Infants with delays were randomly assigned to a home program (1x/week for 8 weeks; mean age=15.5 months, SD=7 months), or a perceptual-motor intervention (2x/week for 8 weeks; mean age=14.3 months, SD=3 months). Measurements: The primary outcome measure was Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure. Results: There was a main effect of time in the GMFM sitting subscale and in two of the COP variables. Interaction of group by time factors indicated significant differences between intervention groups on two COP measures, in favor of the group with perceptual-motor intervention. Limitations: The small number of infants limits the ability to generalize the findings. Conclusions: Although both groups made progress in the GMFM, the COP measures indicated an advantage for the group with perceptual-motor intervention. The COP measures appear sensitive for assessment of infant posture control and quantifying intervention response.
PURPOSE: Functional hypothalamic amenorrhea (FHA) is due to hypothalamic dysregulation. Literature lacks data about prolactin in FHA women, although both prolactin levels and FHA are associated with stress. Moreover, polycystic ovarian morphology is common in FHA and there is an association between FHA and polycystic ovary syndrome. Thus, the aim of this study was to assess prolactin levels in FHA patients and controls with a special focus on factors influencing prolactin levels, that could be considered as "sensors" of the hypothalamic-pituitary dysregulation.
METHODS: In a retrospective cohort study, 140 women with clearly defined FHA were compared to 70 healthy, normally ovulating women matched for age. The main outcome parameter was prolactin. Factors associated with prolactin levels > 12 µg/L were tested using a multivariable binary logistic regression model.
RESULTS: The median prolactin level was 11.5 µg/L (interquartile range, IQR 7.5-14.4), which was similar to the control group (median 10.7, IQR 8.3-14.5; p = 0.065). Only two women had hyperprolactinemia (prolactin > 25 µg/L; 1.4%). In a multivariable binary logistic regression model eating disorder (odds ratio, OR 0.206; p = 0.040), excessive exercise (OR 0.280; p = 0.031) and TSH (OR 1.923; p = 0.020) were significantly associated with prolactin levels > 12 µg/L.
CONCLUSION: Women with FHA have similar prolactin levels to healthy age-matched individuals. Eating disorders and excessive exercise where associated with prolactin levels < 12 µg/L, in contrast to TSH.
Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg and BDQ, 400 mg, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, orally, QD from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
The method for producing the biologically active mucopolysaccharides comprises the treatment of heparin with depolymerizing agent followed by the separation of the end-product by ethanol precipitation. Sodium nitrite is used as depolymerizing agent. Heparin is used at the concentration of 5 mass %, sodium nitrite – 0.0435 M. The incubation is performed at pH 2.5 until NO-2 ions are no longer detectable. Prior to the separation of the end-product, pH of the reaction mixture is adjusted to 7 with sodium hydroxide solution. Ethanol is added at a 2:1 ratio to the reaction mixture. The precipitate is re-dissolved in the aqueous solution of NaCl at pH 3.8.
Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
UNLABELLED: Fractures often cause irreversible harm in Duchenne muscular dystrophy (DMD). This study investigated the trajectory of bone mineral density (BMD) using group-based trajectory modeling and identified that BMD acts as an early-stage indicator of clinically significant bone fragility. The greater the early-stage BMD, the better the 4-year bone health outcome.
PURPOSE: Most Duchenne muscular dystrophy (DMD) children suffer bone loss after long-term glucocorticoid (GC) exposure, which induces scoliosis and fragility fractures. To assess the BMD progression pattern and individual medical risk markers for these phenotypes in young ambulatory boys with DMD, and provide evidence-based suggestions for clinical management of bone health.
METHODS: A retrospective longitudinal cohort study of 153 boys with DMD in West China Second University Hospital (2016-2023) was performed. Group-based trajectory modeling was used to study the BMD progression pattern, and potential predictors were further analyzed by logistic regression and survival analysis.
RESULTS: One hundred and fifty-three participants were included, 71 of which had more than 3 BMD records. Three BMD trajectories were identified. Baseline BMD and age-started GC and were independent predictors of trajectory attribution. The median survival time of the first observation of low BMD in GC-treated DMD boys was 5.32 (95% CI 4.05-6.59) years, and a significant difference was tested (P < 0.001) among the three trajectory groups.
CONCLUSION: BMD may serve as a novel early indicating marker for monitoring bone fragility for DMD. We proposed a bone health risk stratification through BMD progression trajectory that allows us to adapt the osteoporosis warning sign in DMD from a fixed threshold approach to a more individualized strategy, where baseline BMD and age of glucocorticoid initiation can provide an earlier prediction of bone loss. Better management of primary BMD may be able to delay or avoid the onset of adverse bone health outcomes in the fifth year in children with DMD.
INTRODUCTION: Uterine cancer is the most common gynecologic malignancy in women and is projected to surpass ovarian cancer as the deadliest gynecologic malignancy in the United States in 2024. Additionally, rates of advanced and high-risk uterine cancer have been on the rise in the United States, demonstrating a need for innovation in treatment options. There have been multiple recent trials investigating the incorporation of novel agents in the treatment of advanced and recurrent endometrial cancer.
AREAS COVERED: This article will discuss the current landscape of the treatment of advanced and recurrent endometrial cancer, focusing on recent phase III trials published or presented on with the incorporation of immunotherapy and other novel therapeutics while also reviewing promising phase I and II trials in the field. Clinical trials were identified via clinicaltrials.gov and a PubMed literature search was performed (initially February 2024, updated May 2024).
EXPERT OPINION: The treatment field is promising for patients as many of these trials appear to offer progression free and overall survival benefits in a disease with a historically poor prognosis. Molecular profiling of endometrial cancer will be the backbone of treatment paradigms in the future.
Healthy control patients matched to ALL cohort patient on age and sex will be selected for comparison of infection rates during the same calendar year as each ALL cohort participant's study period. Healthy controls will be matched to ALL participants 3:1, with up to a total of 270 controls selected.
Subjects in arm B will not receive niraparib prior to surgery. The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery . Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent.
A hair dye is in the form of a tablet or capsule. The dye is pref. in the form of a round tablet of dia. 1.8 cm, height 0.4 cm, and wt. 1.3 g, contg. mainly plant material. ADVANTAGE - Difficulties and risks of packing liqs. in bottles, or creams in tubes, are avoided. In an example, a mixt. of 20 g of sennae (giving a yellowish shade), 20 g of henna black, 2 g of camomile, 20 g of mucin for thickening/guar flour, 14 g of soap powder and 10 g of potato starch gave 40-80 tablets, giving a greyish colour.
Delivery of glial cell line-derived neurotrophic factor (GDNF) has provided benefits to parkinson's disease patients and is currently being tested in a phase 1/2a clinical trial for ALS patients. However, long-term trophic factor delivery shuts down or prevents dose adjustments in the event of side effects. To address this, the inventors designed a stably integrated, third generation doxycycline regulated vector that allows for inducible and reversible expression of therapeutic molecules. Neural progenitor cells derived from human ipscs were stably transfected with the vector, expanded and transplanted into adult mouse brains. The inventors observed that doxycycline addition and removal caused GDNF expression to be induced and reversed multiple times, suggesting that doxycycline could penetrate grafts and modulate transgene expression in vivo. The inventors' findings provide evidence of the concept of combining gene and stem cell therapy to effectively modulate ectopic protein expression in transplanted cells.
A prescription for clearing blood, dissolving thrombus and preventing sudden death, belonging to the technical field of human body prevention and health care. It is the regulation of physiological functions of the human body by certain drugs. The blood circulation is not stopped until foreign matters in the blood are dissolved from the source of hematogenesis and the blood circulation is promoted, so that the aim of preventing and treating the sudden cardiac and cerebral death is fulfilled. The prescription is developed aiming at the normal circulation of blood. Indicating a high level of blood abnormality based on the relevant data. Blood abnormalities can lead to failure of the blood to function properly, which can lead to a variety of diseases. The cardiovascular and cerebrovascular diseases are the two most dangerous diseases with the greatest danger. The 'blood clearing' in the formula is the treatment principle, and the 'thrombolysis' is the treatment principle, so the formula has the advantages of quick response, short time and less medicine consumption, and the formula mainly comprises Chinese herbal medicines, so the formula has wide medicine sources and low toxicity. It embodies the good medical science of the prescription with good curative effect on cardiovascular and cerebrovascular diseases, low price and low drug cost. The product can be applied to the middle-aged and the elderly people regardless of male and female, and has the effects of treating and preventing diseases and prolonging life.
Our objective was to elucidate the effects of tea consumption on refreshment and stress reduction/recovery through examining the multiple associations among factors such as various physiological responses and task performance. Participants included 20 healthy young men who performed a mental arithmetic task while 11 physiological responses were measured. The experiments were conducted twice under different beverage consumption conditions on separate days. The mental arithmetic task was executed six times in 1 day; participants ingested hot water, green tea, or roasted green tea (hojicha) before each task. Several subjective assessments: subjective fatigue, stress, mental workload, and flow were evaluated after each task. The R-R intervals, heart rate variability spectral components, the Poincaré plot indices (SD1 and SD2) and plethysmogram amplitude tended to decrease during task periods compared to resting periods. Tissue blood volume/flow (TBV, TBF) and near-infrared spectroscopy responses (NIRS) were lower in the tea condition than in the hot water condition. By scrutinizing various indicators, we found that aromatic stimulation of Japanese tea beverages has the potential to induce positive effects, enhance mental task performance, promote refreshment, and alleviate feelings of fatigue. These positive effects were observed even in small quantities and within a short duration, mirroring responses observed in daily consumption.
INTRODUCTION: Understanding the genetic factors contributing to variations in bone mineral density (BMD) and vitamin D could provide valuable insights into the pathogenesis of osteoporosis. This study aimed to evaluate the association of single nucleotide variants in MARK3 (rs11623869), PLCB4 (rs6086746), and GEMIN2 (rs2277458) with BMD in Mexican women.
METHODS: The gene-gene interaction was evaluated in these variants in serum 25(OH)D levels and BMD. A genetic risk score (GRS) was created on the basis of the three genetic variants. Genotyping was performed using predesigned TaqMan assays.
RESULTS: A significant association was found between the rs6086746-A variant and BMD at the total hip, femoral neck, and lumbar spine, in women aged 45 years or older. However, no association was observed between the variants rs11623869 and rs2277458. The rs11623869 × rs2277458 interaction was associated with total hip (p=0.002) and femoral neck BMD (p=0.013). Similarly, for vitamin D levels, we observed an interaction between the variants rs6086746 × rs2277458 (p=0.021). GRS revealed a significant association with total hip BMD (p trend=0.003) and femoral neck BMD (p trend=0.006), as well as increased vitamin D levels (p trend=0.0003). These findings provide evidence of the individual and joint effect of the MARK3, PLCB4, and GEMIN2 variants on BMD and serum vitamin D levels in Mexican women.
DISCUSSION: This knowledge could help to elucidate the interaction mechanism between BMD-related genetic variants and 25OHD, contributing to the determination of the pathogenesis of osteoporosis and its potential implications during early interventions.
BACKGROUND: Prunella vulgaris L., a medicinal and edible homologous plant, is often used to treat conditions such as breast hyperplasia, thyroid enlargement and lymphatic tuberculosis. Research has demonstrated that it is particularly effective in the treatment of mammary gland hyperplasia (MGH). However, the material basis and mechanism of its efficacy are still unclear.
RESULTS: Our results showed that in rats with MGH, polysaccharide from Prunella vulgaris L. (PVP) led to a reduction in the levels of estradiol, prolactin and malondialdehyde, while simultaneously increasing the concentrations of progesterone (P), superoxide dismutase (SOD), manganese superoxide dismutase (MnSOD) and catalase (CAT) in the serum. In addition, results obtained from 16S rRNA sequencing demonstrated that PVP had the capacity to increase the richness and diversity of the intestinal microbiota in MGH rats, as well as modify the structure of the microbiota. Correlation analysis revealed that the levels of P, SOD, MnSOD and CAT were positively associated with Allobaculum, Romboutsia, Faecalibaculum and Clostridium, while negatively correlated with Turicibacter.
CONCLUSIONS: The mechanism of PVP in treating MGH might be through inhibiting the phosphorylation of the AKT-FOXO3a signaling pathway and then activating the expression of downstream antioxidant enzymes, such as MnSOD and CAT. At the same time, PVP could restore intestinal flora homeostasis in rats with MGH by regulating the flora changes of Allobaculum, Romboutsia, Clostridium and Faecalibaculum, thereby reducing oxidative stress in rats with MGH. © 2024 Society of Chemical Industry.
The present invention relates to a composition for skin regeneration, anti-wrinkling, antioxidant, anti-inflammatory and skin whitening effects. According to the present invention, narcissoside promotes collagen generation of fibroblasts and thus has effects of regenerating skin and reducing wrinkles. Narcissoside inhibits generation of NO and thus has an anti-inflammatory effect. Narcissoside also inhibits generation of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
Compositions comprising vitamin E, vitamin C, and white tea extract for treating cutaneous signs of aging are disclosed. The compositions reduce signs of wrinkles and improve other skin conditions, such as increased skin elasticity and skin softness. Moreover, the prevention or treatment of unhealthy skin, such as aged skin or skin overexposed to sunlight, may advantageously be accomplished by the administration of the compositions of the present invention. The compositions includes the combination of a number of different components, which interact to provide the desired improvements to the skin. Further advantageous ingredients of the compositions may comprise, naturally occurring antioxidants extracted from e.g. grape seeds and tomato, an extract comprising glycosaminoglycans, a transition metal component in an amount effective to bind collagen and elastic fibers and thicken skin, and a catechin-based component present in an amount sufficient to inhibit the presence of anti-collagen enzyme in the skin.
Improved compositions for treating dental pulp and root canals comprising a mixture of particulate materials with water-based liquids containing polyvinyl pyrrolidone are provided. Homopolymers and copolymers of polyvinyl pyrrolidone can be used. Optionally, the composition may contain surfactants, humecatants, stabilizers, and other additives. Examples of particulate powders include mixtures of calcium silicate, calcium aluminate, calcium sulfate, and hydroxyapatite. The compositions are particularly suitable for sealing and obturating dental root canals and root apices. The composition provides a stable barrier to bacterial and fluid leakage in the root canal system of a tooth.
The increased incidence of hypertension associated with obstructive sleep apnea (OSA) presents significant physical, psychological, and economic challenges. Peroxisome proliferator-activated receptor gamma (PPARγ) plays a role in both OSA and hypertension, yet the therapeutic potential of PPARγ agonists and antagonists for OSA-related hypertension remains unexplored. Therefore, we constructed a chronic intermittent hypoxia (CIH)-induced hypertension rat model that mimics the pathogenesis of OSA-related hypertension in humans. The model involved administering PPARγ agonist rosiglitazone (RSG), PPARγ antagonist GW9662, or normal saline, followed by regular monitoring of blood pressure and thoracic aorta analysis using staining and electron microscopy. Intriguingly, our results indicated that both RSG and GW9662 appeared to potently counteract CIH-induced hypertension. In silico study suggested that GW9662's antihypertensive effect might mediated through angiotensin II receptor type 1 (AGTR1). Our findings provide insights into the mechanisms of OSA-related hypertension and propose novel therapeutic targets.
PURPOSE:To provide a cancer metastasis suppressing agent containing an alpha-amino acid as an active component, capable of exclusively and specifically suppressing the platelet aggregation-inducing activity of cancer cell, having low toxicity compared with known antiplatelet and utilizable for suppressing and preventing the metastasis of various cancers. CONSTITUTION:An alpha-amino acid, preferably a sulfur-containing amino acid, hydroxyamino acid or basic amino acid is used as a component of the present agent for suppressing the metastasis of cancer. Above all, cysteine, serine and lysine, especially d- and l-cysteine is preferable. The above alpha-amino acid suppresses the platelet aggregation-inducing activity of cancer cell exclusively and specifically with little influence on the platelet aggregation caused by physiological platelet aggregation-inducing substance (e.g. adenosine-2-phosphate). Especially, the relapse of cancer after operation can be suppressed by administering the agent after the surgical treatment or radiotherapy of cancer.
NEW MATERIAL:An optically active acyclonucleoside derivative expressed by formula 1 (R is heterocyclic base; X is halogen, tosyloxy, azido or amino). EXAMPLE:(S)-(+)-1-[(2'-Azido-1'-(hydroxymethyl)ethoxy)methyl]thymine. USE:Useful as a selective biosynthesis inhibitor for nucleic acid and therefore effectively used as a carcinostatic and antiviral agents. PREPARATION:An optically active compound expressed by formula 2 (Ac is acyl) is used as a starting raw material and hydroxyl group of the compound expressed by formula 2 is tosylated according to the reaction formulas (Ph is phenyl; Ts is tosyl). After deacylation, catalytic reduction is carried out to provide a compound expressed by formula 5. Two hydroxyl groups thereof are crosslinked with methylidene groups and then crosslinking is opened in the presence of a Lewis acid catalyst. The heterocyclic base having previously protected with trimethylsilyl group is then reacted therewith in the presence of a Lewis acid catalyst to afford a compound expressed by formula 8, which is subsequently deacylated, etc., to provide the compound expressed by formula 1.
Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.